December 1, 1996Circulation
Hyperhomocysteinemia Confers an Independent Increased Risk of Atherosclerosis in End-Stage Renal Disease and Is Closely Linked to Plasma Folate and Pyridoxine Concentrations
Key result
High plasma homocysteine linked to ~3-fold higher vascular complication risk in ESRD.
- OR 2.9
- 95% CI 1.4-5.8
- P=0.007
- n=176
Why the study?
High total plasma homocysteine is a risk factor for atherosclerosis and its role in vascular complications of end-stage renal disease was evaluated.
Does high total plasma homocysteine concentration increase the risk of vascular complications in patients with end-stage renal disease?
Population
176 dialysis patients with end-stage renal disease
Comparison
Patients with high homocysteine levels versus lower levels
Design
Observational study
Authors
Discussion
Loading...
Member takes
Implication
May flag higher vascular risk in dialysis patients; leaves open whether B-vitamin lowering alters outcomes.
Study Design
Type
Observational (n=176)
Structured PICO
Does high total plasma homocysteine concentration increase the risk of vascular complications in patients with end-stage renal disease?
P
Population
176 dialysis patients (mean age 56.3 years, 44.9% female) evaluated for the association between plasma homocysteine levels and vascular complications.
E
Exposure
High total plasma homocysteine concentration
C
Comparator
Normal reference population / lower homocysteine concentration
O
Outcome
Vascular complications (atherosclerosis)hard clinical
Main Result
Odds Ratio: 2.9 (95% CI 1.4–5.8)
p-value: p=0.007
High total plasma homocysteine is an independent risk factor for atherosclerotic complications in end-stage renal disease, suggesting a potential benefit for higher doses of B vitamins.
Cite This Study
Robinson et al. (1996) conducted an observational in End-stage renal disease (n=176). High total plasma homocysteine concentration (> 27.8 mumol/L) vs. Lower homocysteine concentration was evaluated on Vascular complications (OR 2.9, 95% CI 1.4-5.8, p=0.007). High total plasma homocysteine (>27.8 μmol/L) was independently associated with increased risk of vascular complications in end-stage renal disease (OR 2.9; 95% CI 1.4-5.8; P=0.007).